A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Cancer Oncology

Internal Medicine

Medicine

Cancer Oncology

Internal Medicine

Molecular Biology

Nuclear Medicine

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.2017